N/A N=91 A Transdiagnostic Course for Common Mental Health Problems in Primary Care
Depression · Anxiety
Primary: Overall Satisfaction With Treatment — 22; 21; 23; 23 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=240 Establishing Efficacy of an Inpatient Intervention and Phone App to Reduce Suicidal Risk
Suicidal Ideation · Suicide, Attempted
Primary: Participants With Actual Suicide Attempts as Defined by Columbia Suicide Severity Rating Scale (C-SSRS) — 6; 11; 12; 10 Participants — p=0.71
Phase 1 N=81 Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults
COVID-19
Primary: Frequency of Any New-onset Chronic Medical Conditions (NOCMCs) — 0; 0; 2; 0 Participants
N/A N=15 Lifestyle Behavior Weight Loss Intervention
Obesity · Weight Loss
Primary: Change in Body Weight — 194.1; 191.2; -2.92 pounds — p=0.036
Phase 2 N=19 Cabozantinib and Nivolumab for Carcinoid Tumors
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Phase 1 N=80 First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects
Safety Issues · Tolerance · Idiopathic Pulmonary Fibrosis
Primary: Total Number of Treatment Emergent Adverse Events (AEs) and Serious AEs (SAEs) — 5; 5; 3; 2 Number of events
N/A N=90 Kinesiophobia in Patients With Fibromyalgia Syndrome and Chronic Neck Pain
Fibromyalgia · Neck Pain · Healthy
Primary: Tampa Scale of Kinesiophobia — 41.70; 38.33; 30.83 score on a scale
N/A N=33 The Abuse Liability of a Novel Heated Tobacco Product (IQOS) and Its Feasibility as a Menthol Cigarette Substitute
Tobacco Use
Primary: Percent Change in Average Daily Cigarette Use Per Day From Baseline — 36.8; 80.36 % reduction in cigarettes per day
Phase 2 N=125 Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Primary: Objective Response Rate (ORR) Assessed by the Investigator — 30.6; 20.6 percentage of participants — p=0.2114
Phase 1 N=16 Inhaled Tobramycin in BPD
Bronchopulmonary Dysplasia
Primary: Elevated Serum Tobramycin Trough or Creatinine or Severe Adverse Event — 0; 0; 0; 1 Participants
Phase 1 N=28 Safety and Immunogenicity of HIV DNA-C CN54ENV and Recombinant HIV CN54gp140 Vaccines in Healthy Volunteers
HIV
Primary: Primary Safety Endpoint — 7; 8; 10 Participants — p=>0.05
N/A N=116 Mindful Action for Pain
Chronic Pain
Primary: Brief Pain Inventory (BPI) Pain Interference Subscale Change — 6.77; 7.31; 7.38; 5.40 units on a scale
Phase 1 N=35 Controlled Human Infection Model Challenge/Rechallenge
Shigellosis
Primary: Percentage of Participants With Shigellosis Following Shigella Challenge — 59.1; 80.0; 15.8; 58.3 percentage of participants
N/A N=136 Mechanisms of Mindfulness-based Interventions
Depression · Anxiety · Stress
Primary: Change in BOLD (Blood-oxygen-level-dependent) Mean Signal Change From Baseline to 12 Weeks in Response to Emotional (vs. Neutral) Word Stimuli — 2.315; 2.13; -2.255…
N/A N=34 Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.
Dry Eye
Primary: Change From Baseline in Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Total Score. — -12.6 score on a scale